Vorapaxar Disease Interactions

Vorapaxar increases the risk of bleeding and it is contraindicated in patients with active pathological bleeding such as intracranial hemorrhage or peptic ulcer. In other patients, consider the underlying risk of bleeding before initiating therapy. General risk factors include older age, low body weight, reduced renal or hepatic function, history of bleeding disorders, and use of certain concomitant medications. The use of warfarin and other anticoagulants should be avoided. Bleeding should be suspected in any patient who is hypotensive and has recently undergone coronary angiography, percutaneous coronary intervention (PCI), coronary artery bypass graft surgery (CABG), or any other surgical procedure.

Vorapaxar is contraindicated in patients with a history of stroke, transient ischemic attack (TIA), or intracranial bleeding. The risk of intracranial bleeding is higher in these patients.

No dose adjustment is required in patients with renal dysfunction or mild to moderate hepatic impairment. Vorapaxar is not recommended in patients with severe hepatic impairment due to bleeding risk.